Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Repotrectinib - Turning Point Therapeutics

Drug Profile

Repotrectinib - Turning Point Therapeutics

Alternative Names: Ropotrectinib; TPX 0005

Latest Information Update: 22 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TP Therapeutics
  • Developer Turning Point Therapeutics
  • Class Antineoplastics; Fluorobenzenes; Macrocyclic compounds; Pyrazoles; Small molecules
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors; ROS1 protein inhibitors; Tropomyosin-related kinase antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer; Solid tumours
  • Phase I/II Lymphoma

Most Recent Events

  • 22 Nov 2019 Phase-I/II clinical trials in Lymphoma (In children, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT04094610)
  • 22 Nov 2019 Phase-I/II clinical trials in Solid tumours (In children, Late-stage disease, Second-line therapy or greater, Metastatic disease) in USA (PO) (NCT04094610)
  • 19 Sep 2019 Turning Point Therapeutics plans a phase I/II trial for Solid Tumours and Lymphoma (Late stage disease, Metastatic disease, In children) in December 2019 (NCT04094610)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top